Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | FGFR2 |
| Variant | G338R |
| Impact List | missense |
| Protein Effect | unknown |
| Gene Variant Descriptions | FGFR2 G338R lies within Ig-like C2-type domain 3 of the Fgfr2 protein (UniProt.org). G338R has been identified in sequencing studies (PMID: 38983151), but has not been biochemically characterized and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Nov 2025). |
| Associated Drug Resistance | |
| Category Variants Paths |
FGFR2 mutant FGFR2 G338R |
| Transcript | NM_000141.5 |
| gDNA | chr10:g.121517391C>T |
| cDNA | c.1012G>A |
| Protein | p.G338R |
| Source Database | RefSeq |
| Genome Build | GRCh38/hg38 |
| Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
|---|---|---|---|---|---|
| NM_001320658.1 | chr10:g.121517391C>T | c.1012G>A | p.G338R | RefSeq | GRCh38/hg38 |
| NM_000141.5 | chr10:g.121517391C>T | c.1012G>A | p.G338R | RefSeq | GRCh38/hg38 |
| NM_000141.4 | chr10:g.121517391C>T | c.1012G>A | p.G338R | RefSeq | GRCh38/hg38 |
| NM_001320658 | chr10:g.121517391C>T | c.1012G>A | p.G338R | RefSeq | GRCh38/hg38 |
| NM_000141 | chr10:g.121517391C>T | c.1012G>A | p.G338R | RefSeq | GRCh38/hg38 |
| NM_001320658.2 | chr10:g.121517391C>T | c.1012G>A | p.G338R | RefSeq | GRCh38/hg38 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| FGFR2 G338R | Advanced Solid Tumor | sensitive | Erdafitinib | Preclinical - Cell culture | Actionable | In a preclinical study, Balversa (erdafitinib) inhibited viability of cells expressing FGFR2 G338R in culture (PMID: 40526877). | 40526877 |
| FGFR2 G338R | Advanced Solid Tumor | sensitive | Futibatinib | Preclinical - Cell culture | Actionable | In a preclinical study, Lytgobi (futibatinib) inhibited viability of cells expressing FGFR2 G338R in culture (PMID: 40526877). | 40526877 |
| FGFR2 G338R | Advanced Solid Tumor | sensitive | Pemigatinib | Preclinical - Cell culture | Actionable | In a preclinical study, Pemazyre (pemigatinib) inhibited viability of cells expressing FGFR2 G338R in culture (PMID: 40526877). | 40526877 |
| FGFR2 G338R | Advanced Solid Tumor | sensitive | Fexagratinib | Preclinical - Cell culture | Actionable | In a preclinical study, Fexagratinib (AZD4547) inhibited viability of cells expressing FGFR2 G338R in culture (PMID: 40526877). | 40526877 |